Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled,
single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics
(PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to
participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study
will have 2 cohorts in which participants with CPVT will participate in a 3-period,
randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and
1 dose of matching placebo, with each study drug administered as a single dose.